Mogamulizumab Approved for Two Rare Types of Cutaneous T-cell Lymphoma

Mogamulizumab (Poteligeo) is indicated for  relapsed or refractory mycosis fungoides or Sézary syndrome following at least one prior systemic therapy.

Source: CancerNetwork - September 11, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news